Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pharma Technology Focus - Issue 20
Logistics and Supply Chain Issue: In this issue we explore logistical problems faced by distributors moving sensitive drugs across the Africa, investigate the latest IT tools revolutionising the supply chain for pharmaceuticals and also find out how legislation changes could reverse drug shortages.
Researchers accused of mis-reporting breast cancer clinical trial results
A new study carried out by the Princess Margaret Cancer Centre in Toronto claims that researchers and academics regularly downplay negative results of clinical studies while amplifying their positive aspects.
TauRx Therapeutics Alzheimer’s drug enters a two-phase third trial
Pharmaceutical company TauRx Therepeutics is starting to enroll Alzheimer's patients in its third-stage clinical trial for its experimental new drug LMTX.
University of Texas unveil new lab designed to speed up pre-human clinical trials
A new lab has opened in the University of Texas that is designed to service a gap in the development of new drugs and biotechnology products.
India’s poor possibly used in illegal drug trials without their consent
Some of India's poorest people may have been used as guinea pigs by drug companies to test new drugs without their prior consent, a BBC Newsnight investigation has revealed.
Virtualising the pharma chain – why the cloud is the only way forward
As pharmaceutical supply networks become more and more complex, involving collaboration between hundreds, or even thousands, of entities around the world, traditional supply chain management tools are struggling to keep up. Elly Earls met GT Nexus's Greg Kefer and TraceLink's Shabbir Dahod to find out why moving to the cloud is the only way forward.
Pharmaceutical science - catching up with Armstrong’s doping Peloton
The exposure of Lance Armstrong's doping campaign has rocked not only the world of cycling, but also anyone who had any faith in anti-doping pharmacology and detection. Liam Stoker investigates Armstrong's meticulous use of performance-enhancing drugs, and how pharmaceutical science has finally begun to catch up.
September's top stories: Roche's injectable Herceptin endorsed by EU
Roche has won EU approval for a new injectable formula of its breast cancer drug, Herceptin, while Bayer HealthCare has obtained two separate orphan drug designations from the FDA's Office of Orphan Products Development, for its investigational oral drug riociguat. Pharmaceutical-technology.com wraps up key headlines from September 2013.
Treating type 2 diabetes – a 21st century pandemic
With the number of people diagnosed with type 2 diabetes set to double in the next ten years Dr Valentina Gburcik, GlobalData's analyst in cardiovascular and metabolic disorders, looks at what this will mean for the pharmaceutical industry.
Testing painkillers on humans – why hold back?
Deliberately inflicting carefully controlled painful stimuli on human volunteers could reduce costs and speed up development of new painkilling drugs, according to a new study by Dr Jörn Lötsch of Goethe-University Frankfurt. Elly Earls met the veteran pain researcher to find out if the future of analgesic drug development really is set to be a case of no pain, no gain.
People power: crowdfunding clinical research
With research funding being slashed across the board, could crowdfunding provide the extra cash needed to develop innovative new treatments? Chris Lo discusses people power with the minds behind CureLauncher, a new clinical research crowdfunding platform in the US.
Genting invests $111.8m in TauRx Pharmaceuticals
Genting Management, a subsidiary of Genting Berhad, has invested $31.5m in Singapore-based TauRx Pharmaceuticals, as the first tranche of a $111.8m investment in the pharmaceutical company in return for a 20% equity stake.
Healthcare's black hole: preventing pharmaceutical cargo theft
Cargo theft in the healthcare industry has increased across the globe, and even where actual incidence rates have dropped, the value of stolen items has increased significantly. Dr Nicola Davies reports on a dangerous trend and finds out how security can be improved as drugs make their way from the manufacturing facility to the shelves.
September's top stories: Alzheimer's drug study launched and L'Oreal warned
A new Alzheimer's drug study begins as an inquiry into a UK organization is planned, while scientists make new discoveries involving snake venom. Pharmaceutical-technology.com wraps up the key headlines from September 2012.
Tackling pharmaceutical counterfeits: beyond packaging
With a large proportion of the developing world unable to afford genuine medication, black market counterfeits are the only option for many. As a result, a shocking number of medicines on the market are fakes. Dr Nicola J Davies finds out more about the risk to patients and the huge profit loss incurred by the pharmaceutical industry.
Reckitt Benckiser discontinues sale of Suboxone heroin tablets in the US
Reckitt Benckiser Pharmaceuticals has voluntarily discontinued the sale of Suboxone tablets, a replacement for heroin dependency, after a report suggested the tablets were more likely to be accidently taken by young children.
Virus-Like Particles: Vaccines of Tomorrow?
Virus-like particles represent one of the most exciting new technologies to rapidly produce vaccines. Elisabeth Fischer speaks to industry experts to find out about this cheaper and quicker way to generate effective vaccines with long-lasting protection.
Snapshot: Coronary Artery Disease Global Clinical Trials 2011
An estimated 17 million people die of coronary artery disease worldwide every year, and numbers are rising. While pharmaceutical efforts to find a cure have always been fiercely competitive, few contenders have emerged to challenge time-tested drugs and their generics. But, as this special report snapshot shows, a host of new trials and targeted therapeutics are beginning to show serious dividends.
Combating the Counterfeit Culture
The global counterfeit medicines market is threatening public health and the reputation of the legitimate pharmaceutical industry. Chris Lo finds out the extent of the problem and how the industry and health organisations are responding.
Counterfeit Drugs: What the Doctor Didn't Order
As the number of counterfeit drugs on our streets continues to rise, Paul French asks Global Insight analysts Shuang Lewis and Denise Claux for the lowdown on the potentially deadly pills.